Bank of America’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $663K | Buy |
419,355
+221,506
| +112% | +$374K | ﹤0.01% | 4741 |
|
|
2025
Q4 | $330K | Sell |
197,849
-35,587
| -15% | -$61.6K | ﹤0.01% | 5116 |
|
|
2025
Q3 | $395K | Buy |
233,436
+130,124
| +126% | +$154K | ﹤0.01% | 5936 |
|
|
2025
Q2 | $93.7K | Sell |
103,312
-57,661
| -36% | -$34.2K | ﹤0.01% | 6546 |
|
|
2025
Q1 | $72.6K | Buy |
160,973
+122,858
| +322% | +$72.1K | ﹤0.01% | 6628 |
|
|
2024
Q4 | $19.1K | Sell |
38,115
-1,334,307
| -97% | -$980K | ﹤0.01% | 6854 |
|
|
2024
Q3 | $1.24M | Buy |
1,372,422
+11,497
| +0.8% | +$10.7K | ﹤0.01% | 4911 |
|
|
2024
Q2 | $1.36M | Buy |
1,360,925
+49,644
| +4% | +$54.8K | ﹤0.01% | 4711 |
|
|
2024
Q1 | $1.94M | Buy |
1,311,281
+1,287,428
| +5,397% | +$1.46M | ﹤0.01% | 4473 |
|
|
2023
Q4 | $26K | Buy |
23,853
+17,449
| +272% | +$19.1K | ﹤0.01% | 6737 |
|
|
2023
Q3 | $7.56K | Sell |
6,404
-65,806
| -91% | -$89.5K | ﹤0.01% | 6919 |
|
|
2023
Q2 | $102K | Sell |
72,210
-1,371,569
| -95% | -$1.9M | ﹤0.01% | 6197 |
|
|
2023
Q1 | $2.17M | Buy |
1,443,779
+1,442,750
| +140,209% | +$2.01M | ﹤0.01% | 4282 |
|
|
2022
Q4 | $1.2K | Buy |
1,029
+22
| +2% | +$28 | ﹤0.01% | 7317 |
|
|
2022
Q3 | $1K | Sell |
1,007
-9,993
| -91% | -$14.7K | ﹤0.01% | 7676 |
|
|
2022
Q2 | $18K | Hold |
11,000
| – | – | ﹤0.01% | 7213 |
|
|
2022
Q1 | $17K | Sell |
11,000
-24,243
| -69% | -$37.6K | ﹤0.01% | 7582 |
|
|
2021
Q4 | $86K | Buy |
35,243
+23,651
| +204% | +$55.4K | ﹤0.01% | 6947 |
|
|
2021
Q3 | $29K | Sell |
11,592
-5,837
| -33% | -$15K | ﹤0.01% | 7275 |
|
|
2021
Q2 | $49K | Sell |
17,429
-10,592
| -38% | -$27.4K | ﹤0.01% | 6838 |
|
|
2021
Q1 | $66K | Buy |
28,021
+15,057
| +116% | +$36.2K | ﹤0.01% | 6537 |
|
|
2020
Q4 | $23K | Hold |
12,964
| – | – | ﹤0.01% | 6560 |
|
|
2020
Q3 | $12K | Sell |
12,964
-153,643
| -92% | -$136K | ﹤0.01% | 6408 |
|
|
2020
Q2 | $145K | Buy |
166,607
+150,568
| +939% | +$133K | ﹤0.01% | 5463 |
|
|
2020
Q1 | $13K | Sell |
16,039
-9,431
| -37% | -$9.39K | ﹤0.01% | 6292 |
|
|
2019
Q4 | $23K | Sell |
25,470
-15,335
| -38% | -$12.8K | ﹤0.01% | 6472 |
|
|
2019
Q3 | $39K | Sell |
40,805
-19,895
| -33% | -$20.6K | ﹤0.01% | 6400 |
|
|
2019
Q2 | $67K | Buy |
60,700
+3,621
| +6% | +$4.17K | ﹤0.01% | 6181 |
|
|
2019
Q1 | $74K | Buy |
57,079
+15,389
| +37% | +$19.1K | ﹤0.01% | 6029 |
|
|
2018
Q4 | $38K | Sell |
41,690
-41,125
| -50% | -$63K | ﹤0.01% | 6306 |
|
|
2018
Q3 | $171K | Buy |
82,815
+34,473
| +71% | +$72.4K | ﹤0.01% | 5568 |
|
|
2018
Q2 | $87K | Sell |
48,342
-15,332
| -24% | -$30.9K | ﹤0.01% | 5864 |
|
|
2018
Q1 | $150K | Buy |
63,674
+23,974
| +60% | +$56.2K | ﹤0.01% | 5527 |
|
|
2017
Q4 | $74K | Buy |
39,700
+23,159
| +140% | +$50.6K | ﹤0.01% | 5887 |
|
|
2017
Q3 | $41K | Sell |
16,541
-9,088
| -35% | -$22.5K | ﹤0.01% | 6017 |
|
|
2017
Q2 | $71K | Buy |
25,629
+2,812
| +12% | +$7.86K | ﹤0.01% | 5740 |
|
|
2017
Q1 | $69K | Buy |
22,817
+2,785
| +14% | +$7.91K | ﹤0.01% | 5785 |
|
|
2016
Q4 | $63K | Buy |
20,032
+9,154
| +84% | +$28.1K | ﹤0.01% | 5832 |
|
|
2016
Q3 | $37K | Sell |
10,878
-27,457
| -72% | -$75.8K | ﹤0.01% | 5852 |
|
|
2016
Q2 | $87K | Buy |
38,335
+3,925
| +11% | +$9.62K | ﹤0.01% | 5588 |
|
|
2016
Q1 | $86K | Sell |
34,410
-6,315
| -16% | -$14.1K | ﹤0.01% | 5551 |
|
|
2015
Q4 | $135K | Buy |
40,725
+2,530
| +7% | +$7.56K | ﹤0.01% | 5594 |
|
|
2015
Q3 | $92K | Sell |
38,195
-22,980
| -38% | -$59.5K | ﹤0.01% | 5695 |
|
|
2015
Q2 | $179K | Buy |
61,175
+19,586
| +47% | +$75.9K | ﹤0.01% | 5291 |
|
|
2015
Q1 | $167K | Sell |
41,589
-11,374
| -21% | -$39.4K | ﹤0.01% | 5042 |
|
|
2014
Q4 | $160K | Buy |
52,963
+10,995
| +26% | +$29.7K | ﹤0.01% | 5533 |
|
|
2014
Q3 | $106K | Sell |
41,968
-902
| -2% | -$2.17K | ﹤0.01% | 5961 |
|
|
2014
Q2 | $106K | Buy |
42,870
+35,706
| +498% | +$80.6K | ﹤0.01% | 6093 |
|
|
2014
Q1 | $19K | Sell |
7,164
-1,215
| -15% | -$3.58K | ﹤0.01% | 6931 |
|
|
2013
Q4 | $25K | Buy |
8,379
+742
| +10% | +$2.24K | ﹤0.01% | 6929 |
|
|
2013
Q3 | $24K | Sell |
7,637
-3,332
| -30% | -$10.5K | ﹤0.01% | 6814 |
|
|
2013
Q2 | $35K | Buy |
+10,969
| New | +$35.1K | ﹤0.01% | 6756 |
|
Other funds holding LCTX
BC
VCM
DC
RA
AC
Bank of America's LCTX Position: Q1 2026 in Review
Bank of America increased its Lineage Cell Therapeutics (LCTX) stake by 112% in Q1 2026, buying an estimated $374K and bringing the position to 419,355 shares worth $663K. The position accounts for ﹤0.01% of the portfolio, ranked #4741.
Bank of America first reported a position in LCTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.17M in Q1 2023. 130 funds tracked by Wall St. Rank hold LCTX as of Q1 2026.
- Bank of America held 419,355 shares of Lineage Cell Therapeutics worth $663K as of Q1 2026.
- Bank of America bought 221,506 Lineage Cell Therapeutics shares in Q1 2026, an estimated $374K.
- Lineage Cell Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #4741 holding.
- Bank of America first reported a position in Lineage Cell Therapeutics in Q2 2013 and has held it in 52 quarters since.
- Bank of America's Lineage Cell Therapeutics position peaked at $2.17M in Q1 2023.
- 130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.